Can RXT’s AMD Deal Justify Its Sixfold Run?Rackspace Technology, Inc.BATS:RXTTradeThePoolRackspace Technology (RXT) has staged one of 2026's more dramatic reinventions. The stock has climbed more than sixfold this year, including a roughly 30% jump after the company signed a definitive agreement with AMD to deploy 30 megawatts of AI compute across its data centers. The infrastructure will run on AMD Instinct MI355X and MI350P GPUs alongside EPYC CPUs, packaged as a unified Enterprise AI Cloud, with a phased rollout from late 2026 through 2028. The deal formalizes a May memorandum of understanding and reframes a former commodity cloud provider as a contender in governed enterprise AI. The strategic logic is coherent. Alongside the AMD pact, Rackspace approved a 15% global workforce reduction, taking $14 million to $19 million in one-time charges to unlock $75 million to $85 million in annualized run-rate savings. Management is redirecting that capital away from legacy public cloud delivery and toward forward-deployed engineering and the AMD buildout. In effect, the company is funding its own pivot, retreating from the low-margin turf it was losing to hyperscalers and moving toward higher-margin, compliance-bound workloads. The bull case rests on a real gap in the market. Regulated sectors such as healthcare have lagged in AI adoption because they cannot move sensitive workloads onto public hyperscalers, and Rackspace is pitching single-operator accountability from silicon to outcomes as the answer. If it executes, a dedicated 30 MW of sovereign-grade capacity is meaningful, and early healthcare interest points to genuine demand. This is the most defensible part of the story, and it explains why the market rewarded the announcement so aggressively. The risks, however, are just as concrete, and the price has run ahead of them. The agreement is conditional: each deployment requires a separate commercial contract, and AMD has no obligation to approve any of them, so the 30 MW is a ceiling rather than a commitment. The fundamentals remain weak, with a trailing net loss of $146 million on $2.7 billion in revenue and no profitability expected this year. Analysts are unconvinced, holding an average price target near $2.50 against a share price above $7. The pivot is credible, and the catalyst is real, but at current levels, RXT is priced for flawless execution of a multi-year buildout that is not yet locked in.